Cargando…
Targeting the A(3) adenosine receptor to prevent and reverse chemotherapy-induced neurotoxicities in mice
Cisplatin is used to combat solid tumors. However, patients treated with cisplatin often develop cognitive impairments, sensorimotor deficits, and peripheral neuropathy. There is no FDA-approved treatment for these neurotoxicities. We investigated the capacity of a highly selective A(3) adenosine re...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800287/ https://www.ncbi.nlm.nih.gov/pubmed/35093182 http://dx.doi.org/10.1186/s40478-022-01315-w |
_version_ | 1784642227950059520 |
---|---|
author | Singh, Anand Kumar Mahalingam, Rajasekaran Squillace, Silvia Jacobson, Kenneth A. Tosh, Dilip K. Dharmaraj, Shruti Farr, Susan A. Kavelaars, Annemieke Salvemini, Daniela Heijnen, Cobi J. |
author_facet | Singh, Anand Kumar Mahalingam, Rajasekaran Squillace, Silvia Jacobson, Kenneth A. Tosh, Dilip K. Dharmaraj, Shruti Farr, Susan A. Kavelaars, Annemieke Salvemini, Daniela Heijnen, Cobi J. |
author_sort | Singh, Anand Kumar |
collection | PubMed |
description | Cisplatin is used to combat solid tumors. However, patients treated with cisplatin often develop cognitive impairments, sensorimotor deficits, and peripheral neuropathy. There is no FDA-approved treatment for these neurotoxicities. We investigated the capacity of a highly selective A(3) adenosine receptor (AR) subtype (A(3)AR) agonist, MRS5980, to prevent and reverse cisplatin-induced neurotoxicities. MRS5980 prevented cisplatin-induced cognitive impairment (decreased executive function and impaired spatial and working memory), sensorimotor deficits, and neuropathic pain (mechanical allodynia and spontaneous pain) in both sexes. At the structural level, MRS5980 prevented the cisplatin-induced reduction in markers of synaptic integrity. In-situ hybridization detected Adora3 mRNA in neurons, microglia, astrocytes and oligodendrocytes. RNAseq analysis identified 164 genes, including genes related to mitochondrial function, of which expression was changed by cisplatin and normalized by MRS5980. Consistently, MRS5980 prevented cisplatin-induced mitochondrial dysfunction and decreased signs of oxidative stress. Transcriptomic analysis showed that the A(3)AR agonist upregulates genes related to repair pathways including NOTCH1 signaling and chromatin modification in the cortex of cisplatin-treated mice. Importantly, A(3)AR agonist administration after completion of cisplatin treatment resolved cognitive impairment, neuropathy and sensorimotor deficits. Our results highlight the efficacy of a selective A(3)AR agonist to prevent and reverse cisplatin-induced neurotoxicities via preventing brain mitochondrial damage and activating repair pathways. An A(3)AR agonist is already in cancer, clinical trials and our results demonstrate management of neurotoxic side effects of chemotherapy as an additional therapeutic benefit. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-022-01315-w. |
format | Online Article Text |
id | pubmed-8800287 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-88002872022-02-02 Targeting the A(3) adenosine receptor to prevent and reverse chemotherapy-induced neurotoxicities in mice Singh, Anand Kumar Mahalingam, Rajasekaran Squillace, Silvia Jacobson, Kenneth A. Tosh, Dilip K. Dharmaraj, Shruti Farr, Susan A. Kavelaars, Annemieke Salvemini, Daniela Heijnen, Cobi J. Acta Neuropathol Commun Research Cisplatin is used to combat solid tumors. However, patients treated with cisplatin often develop cognitive impairments, sensorimotor deficits, and peripheral neuropathy. There is no FDA-approved treatment for these neurotoxicities. We investigated the capacity of a highly selective A(3) adenosine receptor (AR) subtype (A(3)AR) agonist, MRS5980, to prevent and reverse cisplatin-induced neurotoxicities. MRS5980 prevented cisplatin-induced cognitive impairment (decreased executive function and impaired spatial and working memory), sensorimotor deficits, and neuropathic pain (mechanical allodynia and spontaneous pain) in both sexes. At the structural level, MRS5980 prevented the cisplatin-induced reduction in markers of synaptic integrity. In-situ hybridization detected Adora3 mRNA in neurons, microglia, astrocytes and oligodendrocytes. RNAseq analysis identified 164 genes, including genes related to mitochondrial function, of which expression was changed by cisplatin and normalized by MRS5980. Consistently, MRS5980 prevented cisplatin-induced mitochondrial dysfunction and decreased signs of oxidative stress. Transcriptomic analysis showed that the A(3)AR agonist upregulates genes related to repair pathways including NOTCH1 signaling and chromatin modification in the cortex of cisplatin-treated mice. Importantly, A(3)AR agonist administration after completion of cisplatin treatment resolved cognitive impairment, neuropathy and sensorimotor deficits. Our results highlight the efficacy of a selective A(3)AR agonist to prevent and reverse cisplatin-induced neurotoxicities via preventing brain mitochondrial damage and activating repair pathways. An A(3)AR agonist is already in cancer, clinical trials and our results demonstrate management of neurotoxic side effects of chemotherapy as an additional therapeutic benefit. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-022-01315-w. BioMed Central 2022-01-29 /pmc/articles/PMC8800287/ /pubmed/35093182 http://dx.doi.org/10.1186/s40478-022-01315-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Singh, Anand Kumar Mahalingam, Rajasekaran Squillace, Silvia Jacobson, Kenneth A. Tosh, Dilip K. Dharmaraj, Shruti Farr, Susan A. Kavelaars, Annemieke Salvemini, Daniela Heijnen, Cobi J. Targeting the A(3) adenosine receptor to prevent and reverse chemotherapy-induced neurotoxicities in mice |
title | Targeting the A(3) adenosine receptor to prevent and reverse chemotherapy-induced neurotoxicities in mice |
title_full | Targeting the A(3) adenosine receptor to prevent and reverse chemotherapy-induced neurotoxicities in mice |
title_fullStr | Targeting the A(3) adenosine receptor to prevent and reverse chemotherapy-induced neurotoxicities in mice |
title_full_unstemmed | Targeting the A(3) adenosine receptor to prevent and reverse chemotherapy-induced neurotoxicities in mice |
title_short | Targeting the A(3) adenosine receptor to prevent and reverse chemotherapy-induced neurotoxicities in mice |
title_sort | targeting the a(3) adenosine receptor to prevent and reverse chemotherapy-induced neurotoxicities in mice |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800287/ https://www.ncbi.nlm.nih.gov/pubmed/35093182 http://dx.doi.org/10.1186/s40478-022-01315-w |
work_keys_str_mv | AT singhanandkumar targetingthea3adenosinereceptortopreventandreversechemotherapyinducedneurotoxicitiesinmice AT mahalingamrajasekaran targetingthea3adenosinereceptortopreventandreversechemotherapyinducedneurotoxicitiesinmice AT squillacesilvia targetingthea3adenosinereceptortopreventandreversechemotherapyinducedneurotoxicitiesinmice AT jacobsonkennetha targetingthea3adenosinereceptortopreventandreversechemotherapyinducedneurotoxicitiesinmice AT toshdilipk targetingthea3adenosinereceptortopreventandreversechemotherapyinducedneurotoxicitiesinmice AT dharmarajshruti targetingthea3adenosinereceptortopreventandreversechemotherapyinducedneurotoxicitiesinmice AT farrsusana targetingthea3adenosinereceptortopreventandreversechemotherapyinducedneurotoxicitiesinmice AT kavelaarsannemieke targetingthea3adenosinereceptortopreventandreversechemotherapyinducedneurotoxicitiesinmice AT salveminidaniela targetingthea3adenosinereceptortopreventandreversechemotherapyinducedneurotoxicitiesinmice AT heijnencobij targetingthea3adenosinereceptortopreventandreversechemotherapyinducedneurotoxicitiesinmice |